CDH2 and non-small cell lung carcinoma: To further validate these novel players in lung cancer cell migration, we selected five candidates—DSE, CPA4, FLNC, TUBB6, and BICC1—and the positive control CDH2, which were upregulated in fast cells and also associated with poor overall survival in NSCLC patients.